Celladon Corporation is a biotechnology company focused on developing cutting edge treatments for cardiovascular diseases. Celladon’s lead development program is designed to treat congestive heart failure by using a recombinant adeno-associated viral (rAAV) vector to restore production of an enzyme that regulates calcium cycling and contractility in heart muscle cells. Celladon's first generation product, MYDICAR®, replaces the gene for the SERCA2a enzyme, which is known to be depleted in severe heart failure. MYDICAR is currently being tested in Phase 1 and 2 clinical trials.

 The following materials are available for your use in PDF format:

1) Celladon Corporation Tri-Fold Brochure

2) Product Development Backgrounder

3) MYDICAR® Fact Sheet